Trial Profile
A Phase II Study of CTLA Blockade by Ipilimumab Plus Androgen Suppression Therapy in Patients With an Incomplete Response to AST Alone for Metastatic Prostate Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Antiandrogens
- Indications Adenocarcinoma; Cancer metastases; Prostate cancer
- Focus Therapeutic Use
- 23 Sep 2020 Status changed from active, no longer recruiting to completed.
- 25 Jul 2019 Planned End Date changed from 28 Sep 2018 to 29 May 2020.
- 15 May 2018 Planned End Date changed from 18 Nov 2018 to 28 Sep 2018.